Safety of voriconazole in a patient with CYP2C92/CYP2C92 genotype

被引：38

作者：

Geist, Marcus J. P. ^{[1
]}

Egerer, Gerlinde ^{[1
]}

Burhenne, Juergen ^{[1
]}

Mikus, Gerd ^{[1
]}

机构：

[1] Univ Heidelberg, Dept Internal Med 6, D-69120 Heidelberg, Germany

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 09期

关键词：

D O I：

10.1128/AAC.00551-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页码：3227 / 3228

页数：2

共 10 条

[1] Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population [J].

Burian, M ;

Grösch, S ;

Tegeder, I ;

Geisslinger, G .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) :518-521

[2] Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole [J].

Hyland, R ;

Jones, BC ;

Smith, DA .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) :540-547

[3] Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data [J].

Lee, CR ;

Goldstein, JA ;

Pieper, JA .

PHARMACOGENETICS, 2002, 12 (03) :251-263

[4]

MIKUS G, IN PRESS CLIN PHARM

[5] Development and validation of a high-performance liquid chromatography assay for voriconazole [J].

Pennick, GJ ;

Clark, M ;

Sutton, DA ;

Rinaldi, MG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2348-2350

[6] Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens [J].

Purkins, L ;

Wood, N ;

Ghahramani, P ;

Greenhalgh, K ;

Allen, MJ ;

Kleinermans, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2546-2553

[7] Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics [J].

Rengelshausen, J ;

Banfield, M ;

Riedel, KD ;

Burhenne, J ;

Weiss, J ;

Thomsen, T ;

Walter-Sack, I ;

Haefeli, WE ;

Mikus, G .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (01) :25-33

[8] Bioanalytical Method Validation—A Revisit with a Decade of Progress [J].

Vinod P. Shah ;

Kamal K. Midha ;

John W. A. Findlay ;

Howard M. Hill ;

James D. Hulse ;

Iain J. McGilveray ;

Gordon McKay ;

Krys J. Miller ;

Rabindra N. Patnaik ;

Mark L. Powell ;

Alfred Tonelli ;

C. T. Viswanathan ;

Avraham Yacobi .

Pharmaceutical Research, 2000, 17 (12) :1551-1557

[9]

Shimizu Takako, 2003, Drug Metab Pharmacokinet, V18, P48, DOI 10.2133/dmpk.18.48

[10] Drug therapy - Drug metabolism and variability among patients in drug response [J].

Wilkinson, GR .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (21) :2211-2221

← 1 →

Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype

Safety of voriconazole in a patient with CYP2C92/CYP2C92 genotype